ICD-10-PCS Billable Code

D916BYZ

Brachytherapy Salivary Glands to None with Other Isotope, Low Dose Rate (LDR) Approach

Procedural Specifications

Clinical Axis Detail Definition
SectionD Radiation Therapy
Body System9 Ear, Nose, Mouth and Throat
Operation1 Brachytherapy
Body Part6 Salivary Glands
ApproachB Low Dose Rate (LDR)
DeviceY Other Isotope
QualifierZ None

Procedure Overview

Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.

The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.

Anatomy & Axis Detail

Salivary Glands

The salivary glands, most often the parotid or submandibular glands when brachytherapy is used, may receive implanted radioactive sources when a tumor is localized enough to allow interstitial placement, typically as a boost following resection or external radiation. Because glandular tissue is arranged around branching ducts and is closely associated with the facial nerve in the parotid, source placement demands attention to these structures to avoid unnecessary injury during catheter insertion. This approach allows a concentrated dose to residual or high-risk tissue while limiting radiation exposure to the surrounding gland and adjacent skin compared to broader external fields. Given that saliva production depends on preserving as much healthy glandular tissue as possible, brachytherapy's localized nature is often chosen specifically to protect function in the uninvolved portions of the gland.

Modality Qualifier: Low Dose Rate (LDR)

Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.

Isotope: Other Isotope

Other Isotope is the residual code for a radioactive source used in brachytherapy or systemic radiopharmaceutical therapy that does not correspond to one of the specifically named isotopes in this axis, such as Ir-192, I-125, or Sr-89. It is selected when documentation identifies a distinct radionuclide, or an isotope newly adopted into practice, that lacks its own dedicated value.

Coding & Documentation

Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.

Commonly Confused With

Beam RadiationThe main point of confusion is with Beam Radiation, since both can treat the same tumor types in this region - the deciding factor is whether the source is implanted at the site (brachytherapy) or aimed from outside the body (beam).
Stereotactic RadiosurgeryIt can also be confused with Stereotactic Radiosurgery, which uses external, highly focused beams rather than an implanted source, even though both aim to concentrate dose precisely.